Quick Freezing-Induced Au Nanoparticle Aggregates (QFIAAs) for Near-IR (NIR) Surface-Enhanced Raman Scattering (SERS) Substrates.

Here, we report a simple method to prepare near-IR (NIR) surface-enhanced Raman scattering (SERS) substrates by quickly freezing a citrate-capped Au nanoparticle (AuNP) solution in liquid nitrogen, followed by thawing it at room temperature. This process aggregates AuNPs in a controlled manner by forming ice crystals with smaller grain sizes when compared to a slow freezing process. The resulting smaller AuNP aggregates remain suspended in solution long enough to conduct high-throughput chemical analysis in a microwell plate using the NIR SERS spectroscopy.

Mechanism of Amplified Photoacoustic Effect for Silica-Coated Spherical Gold Nanoparticles.

Plasmonic nanomaterials are effective photoacoustic (PA) contrast agents with diverse biomedical applications. While silica coatings on gold nanoparticles (AuNPs) have been demonstrated to increase PA efficiency, the underlying mechanism remains elusive. Here, we systematically investigated the impact of silica coatings on PA generation under picosecond and nanosecond laser pulses.

User-centered design and development of a web-based tool to support healthy feeding practices by parents of urban minority youth at risk for childhood obesity.

Objectives: Technology, mobile health (mHealth), and "eHealth" are broadly used in childhood overweight and obesity interventions. However, the impact of technology-based interventions where parents or caregivers are involved is unclear. Thus, the objective of this manuscript is to provide valuable insights about the development of a parent-child web-based tool to promote healthy eating among preadolescents.

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.

Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.

Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.

Design, Setting, And Participants: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis.